logo-loader
viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals hails further boost to its growing Sandoz tacrolimus revenues across Canada

As of November 4 last year, a major health authority mandated that Sandoz tacrolimus be dispensed to all new patients in the province

Aequus Pharmaceuticals Inc. -
The product is used to prevent patient rejection after organ transplants

Aequus Pharmaceuticals Inc (CVE:AQS) (OCTMKTS:AQSZF) on Thursday unveiled positive news on its tacrolimus drug in British Columbia, which is used to prevent patient rejection after organ transplants. 

As of November 4, 2019,  a major health authority mandated that the drug Sandoz tacrolimus is to be dispensed to all new patients requiring tacrolimus for prophylaxis in the province, the pharma group said in a statement. 

READ: Aequus to broaden patient reimbursement in Canada for glaucoma-treatment product Vistitan

Aequus receives a revenue share of the product from its partner Sandoz.

"This is great news from our home province,” Doug Janzen, the chief executive of Aequus, told investors.

"Our commercial and market access teams have worked hard to provide the province with an alternative to the branded product, Prograf, which currently sells roughly $20M in product annually in British Columbia.

"This access will provide an added boost to our already impressive performance of growing Sandoz tacrolimus revenues across Canada and is the second piece of positive reimbursement news that Aequus has had regarding its growing product portfolio so far in 2020."

Between 2011 and 2018, British Columbia conducted 2,750 heart, kidney, or liver transplants.

As of 2018, 4,870 people living with organ transplantation resided in British Columbia, representing around 20% of transplant patients in Canada.

A first line calcineurin inhibitor treatment

Tacrolimus is recommended as a first-line calcineurin inhibitor treatment by the British Columbia transplant consensus guidelines and is prescribed in over 90% of new kidney transplant patients.

Earlier this month, Aequus said it had advanced filings for provincial reimbursement in Quebec and British Columbia for its flagship glaucoma-treatment product Vistitan.

If successful, the additional coverage would advance sales in the second and third largest markets in Canada and would trigger an increase in the percentage of total revenue that Aequus receives from its partner.

Contact the author at [email protected]

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.11 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $8.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aequus Pharmaceuticals acquires Canadian rights to therapies for Dry Eye

Aequus Pharmaceuticals (CVE:AQS-OTCQB-) Chairman and CEO Doug Janzen sat down with Steve Darling from Proactive Investors Vancouver to discuss the company acquiring the Canadian rights to a line of products that help people deal with Dry Eye. 

on 13/3/19

2 min read